CN111253297A - Process method for preparing 5-methoxy-2-methylindole - Google Patents
Process method for preparing 5-methoxy-2-methylindole Download PDFInfo
- Publication number
- CN111253297A CN111253297A CN202010241252.9A CN202010241252A CN111253297A CN 111253297 A CN111253297 A CN 111253297A CN 202010241252 A CN202010241252 A CN 202010241252A CN 111253297 A CN111253297 A CN 111253297A
- Authority
- CN
- China
- Prior art keywords
- methoxy
- acid
- methylindole
- preparing
- reaction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract description 26
- VSWGLJOQFUMFOQ-UHFFFAOYSA-N 5-methoxy-2-methyl-1h-indole Chemical compound COC1=CC=C2NC(C)=CC2=C1 VSWGLJOQFUMFOQ-UHFFFAOYSA-N 0.000 title claims abstract description 24
- 238000006243 chemical reaction Methods 0.000 claims abstract description 31
- XLSMFKSTNGKWQX-UHFFFAOYSA-N hydroxyacetone Chemical compound CC(=O)CO XLSMFKSTNGKWQX-UHFFFAOYSA-N 0.000 claims abstract description 20
- 239000002994 raw material Substances 0.000 claims abstract description 10
- 239000003054 catalyst Substances 0.000 claims abstract description 8
- BHAAPTBBJKJZER-UHFFFAOYSA-N p-anisidine Chemical compound COC1=CC=C(N)C=C1 BHAAPTBBJKJZER-UHFFFAOYSA-N 0.000 claims abstract description 8
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 18
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 18
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 12
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 12
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 9
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 claims description 8
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 6
- 229940098779 methanesulfonic acid Drugs 0.000 claims description 6
- DLYUQMMRRRQYAE-UHFFFAOYSA-N tetraphosphorus decaoxide Chemical compound O1P(O2)(=O)OP3(=O)OP1(=O)OP2(=O)O3 DLYUQMMRRRQYAE-UHFFFAOYSA-N 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 5
- RFFLAFLAYFXFSW-UHFFFAOYSA-N 1,2-dichlorobenzene Chemical compound ClC1=CC=CC=C1Cl RFFLAFLAYFXFSW-UHFFFAOYSA-N 0.000 claims description 4
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims description 4
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 claims description 4
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 claims description 4
- MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 claims description 4
- LQNUZADURLCDLV-UHFFFAOYSA-N nitrobenzene Chemical compound [O-][N+](=O)C1=CC=CC=C1 LQNUZADURLCDLV-UHFFFAOYSA-N 0.000 claims description 4
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims description 4
- ITMCEJHCFYSIIV-UHFFFAOYSA-N triflic acid Chemical compound OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 claims description 4
- 235000005074 zinc chloride Nutrition 0.000 claims description 4
- 239000011592 zinc chloride Substances 0.000 claims description 4
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 claims description 3
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 3
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 claims description 2
- LZDKZFUFMNSQCJ-UHFFFAOYSA-N 1,2-diethoxyethane Chemical compound CCOCCOCC LZDKZFUFMNSQCJ-UHFFFAOYSA-N 0.000 claims description 2
- JWUJQDFVADABEY-UHFFFAOYSA-N 2-methyltetrahydrofuran Chemical compound CC1CCCO1 JWUJQDFVADABEY-UHFFFAOYSA-N 0.000 claims description 2
- JHNLZOVBAQWGQU-UHFFFAOYSA-N 380814_sial Chemical compound CS(O)(=O)=O.O=P(=O)OP(=O)=O JHNLZOVBAQWGQU-UHFFFAOYSA-N 0.000 claims description 2
- GSNUFIFRDBKVIE-UHFFFAOYSA-N DMF Natural products CC1=CC=C(C)O1 GSNUFIFRDBKVIE-UHFFFAOYSA-N 0.000 claims description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 claims description 2
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 claims description 2
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 claims description 2
- 229940092714 benzenesulfonic acid Drugs 0.000 claims description 2
- SBZXBUIDTXKZTM-UHFFFAOYSA-N diglyme Chemical compound COCCOCCOC SBZXBUIDTXKZTM-UHFFFAOYSA-N 0.000 claims description 2
- YKYONYBAUNKHLG-UHFFFAOYSA-N n-Propyl acetate Natural products CCCOC(C)=O YKYONYBAUNKHLG-UHFFFAOYSA-N 0.000 claims description 2
- NSBIQPJIWUJBBX-UHFFFAOYSA-N n-methoxyaniline Chemical compound CONC1=CC=CC=C1 NSBIQPJIWUJBBX-UHFFFAOYSA-N 0.000 claims description 2
- 229940090181 propyl acetate Drugs 0.000 claims description 2
- 239000002904 solvent Substances 0.000 claims description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 2
- HPGGPRDJHPYFRM-UHFFFAOYSA-J tin(iv) chloride Chemical compound Cl[Sn](Cl)(Cl)Cl HPGGPRDJHPYFRM-UHFFFAOYSA-J 0.000 claims description 2
- XJDNKRIXUMDJCW-UHFFFAOYSA-J titanium tetrachloride Chemical compound Cl[Ti](Cl)(Cl)Cl XJDNKRIXUMDJCW-UHFFFAOYSA-J 0.000 claims description 2
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 claims description 2
- 239000008096 xylene Substances 0.000 claims description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 14
- 238000004128 high performance liquid chromatography Methods 0.000 description 11
- 230000015572 biosynthetic process Effects 0.000 description 7
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 7
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 238000003786 synthesis reaction Methods 0.000 description 7
- 239000003814 drug Substances 0.000 description 6
- 238000010992 reflux Methods 0.000 description 6
- 229940079593 drug Drugs 0.000 description 5
- 238000001228 spectrum Methods 0.000 description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- 125000000168 pyrrolyl group Chemical group 0.000 description 4
- 238000005160 1H NMR spectroscopy Methods 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 3
- 238000004321 preservation Methods 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- PVRSIFAEUCUJPK-UHFFFAOYSA-N (4-methoxyphenyl)hydrazine Chemical compound COC1=CC=C(NN)C=C1 PVRSIFAEUCUJPK-UHFFFAOYSA-N 0.000 description 2
- FQHCPFMTXFJZJS-UHFFFAOYSA-N (4-methoxyphenyl)hydrazine;hydrochloride Chemical compound Cl.COC1=CC=C(NN)C=C1 FQHCPFMTXFJZJS-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000001212 derivatisation Methods 0.000 description 2
- 238000006193 diazotization reaction Methods 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 125000001041 indolyl group Chemical group 0.000 description 2
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 238000013341 scale-up Methods 0.000 description 2
- 238000001308 synthesis method Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 229910021627 Tin(IV) chloride Inorganic materials 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- OPQARKPSCNTWTJ-UHFFFAOYSA-L copper(ii) acetate Chemical compound [Cu+2].CC([O-])=O.CC([O-])=O OPQARKPSCNTWTJ-UHFFFAOYSA-L 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000004880 explosion Methods 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 229910000510 noble metal Inorganic materials 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 238000000643 oven drying Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000006798 ring closing metathesis reaction Methods 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Indole Compounds (AREA)
Abstract
The invention discloses a process method for preparing 5-methoxy-2-methylindole, which comprises the following steps: p-methoxyaniline is used as a raw material and reacts with hydroxyacetone under the action of a catalyst to obtain the 5-methoxy-2-methylindole. The reaction yield is high, and the product purity is high.
Description
Technical Field
The invention relates to the field of medical intermediates, in particular to a process method for preparing 5-methoxy-2-methylindole.
Background
Indole is an aromatic heterocyclic compound, and the chemical structure of the indole is formed by combining a benzene ring and a pyrrole ring. Indole is a most common chemical medicine structural skeleton, and due to high biological activity of indole, indole occupies a place in medicines in multiple treatment fields of hypertension resistance, antiproliferation, virus resistance, tumor resistance, pain relief, inflammation resistance, bacteria resistance and the like. For example, the number of drugs on the market containing indole skeleton is 112 from the recorded drug information in the Bigde database.
5-Methoxy-2-Methylindole (5-Methoxy-2-Methylindole, CAS:1076-74-0) is a very important electron-rich indole building block in indole structures. The positions of 5-methoxy-2-methylindole available for derivatization are very many, and hydrogen on a pyrrole ring, methyl on the pyrrole ring, nitrogen on the pyrrole ring, hydrogen on a benzene ring and oxygen on a benzene ring can be correspondingly derivatized, so that the 5-methoxy-2-methylindole is widely applied to drug synthesis, and the derivatization reaction recorded on Scifinder by light is more than 2000.
The currently reported synthesis routes of 5-methoxy-2-methylindole with practical value mainly comprise two routes, respectively as follows:
the first route is the one reported in pharmaceutical Chemistry (Journal of Medicinal Chemistry; vol.49; nb.1; (2006); p.135-158) in 2006,
the route adopts a 2-step synthesis method, 4-methoxy phenylhydrazine or 4-methoxy phenylhydrazine hydrochloride is taken as an initial raw material, and is condensed with acetone, and then Fisher indole cyclization is carried out by using zinc chloride to obtain the 5-methoxy-2-methylindole.
There are three more serious problems with this approach: firstly, the steps are long, and the operation is complicated; secondly, the raw material 4-methoxy phenylhydrazine or 4-methoxy phenylhydrazine hydrochloride in the first step is obtained by diazotizing p-anisidine and then reducing the diazotization reaction, the diazotization reaction has explosiveness and great hidden danger to the personal safety of operators, the whole life cycle of the raw material does not meet the requirements of green environmental protection, and simultaneously, the raw material has higher price and does not meet the economic principle; thirdly, the second step requires the use of a large amount of zinc chloride, and a large amount of viscous metal salts are generated during the post-treatment of the reaction, which makes the post-treatment difficult. These three problems severely limit the further application of the process and also make the kilogram scale and ten kilogram scale up of the product more difficult.
The second route is the one reported in Journal of the American chemical society, vol.134, nb.22, (2012), p.9098-9101 in 2012,
the route adopts a 1-step synthesis method, wherein p-anisidine is taken as a starting material, and is subjected to ring closure with acetone under the action of palladium acetate, copper acetate and oxygen to obtain the 5-methoxy-2-methylindole.
This method also has two more serious problems: firstly, the expensive noble metal catalyst palladium acetate is used, so that the economic principle is not met, a small amount of heavy metal is remained in the product, and the use of the product in the subsequent drug synthesis is influenced; secondly, oxygen needs to be introduced in the reaction process, so that not only is the operation difficulty increased, but also the explosion risk of the method is increased by more than one order of magnitude when the method is amplified in a larger amount. Both of these problems severely limit further applications of the process and also make kilogram and ten kilogram scale-up of the product difficult.
In order to solve the problems of high price of key raw materials, poor process safety and complex post-treatment of the existing process route of the 5-methoxy-2-methylindole, the method for synthesizing the 5-methoxy-2-methylindole, which has the advantages of reasonable route design, low price of raw materials, convenience in operation and high safety, is very important.
Disclosure of Invention
In order to overcome the defects in the prior art, the embodiment of the invention provides a process method for preparing 5-methoxy-2-methylindole, which has high reaction yield and high product purity.
In order to achieve the above purpose, the embodiments of the present application disclose a process for preparing 5-methoxy-2-methylindole, which comprises the following steps:
p-methoxyaniline is used as a raw material and reacts with hydroxyacetone under the action of a catalyst to obtain the 5-methoxy-2-methylindole.
Preferably, the catalyst is one or more of acetic acid, trifluoroacetic acid, aluminum trichloride, zinc chloride, titanium tetrachloride, stannic chloride, methanesulfonic acid, trifluoromethanesulfonic acid, phosphoric acid, sulfuric acid, p-toluenesulfonic acid, eaton's reagent, phosphorus pentoxide and benzenesulfonic acid.
Preferably, the reaction of the methoxyaniline and the hydroxyacetone is carried out in a solvent, which is one or more of dichloromethane, 1, 2-dichloroethane, o-dichlorobenzene, nitrobenzene, chlorobenzene, methanesulfonic acid, acetic acid, trifluoromethanesulfonic acid, diethyl ether, tert-butyl methyl ether, tetrahydrofuran, 2-methyl tetrahydrofuran, dioxane, ethylene glycol dimethyl ether, ethylene glycol diethyl ether, diethylene glycol dimethyl ether, DMF, DMSO, toluene, xylene, ethyl acetate, propyl acetate, acetonitrile, dioxane.
Preferably, the amount of the hydroxyacetone is as follows: 0.5 to 10 equivalents.
Preferably, the catalyst is used in the following amount: 0.001 to 100 equivalents.
Preferably, the reaction temperature is-20 to 200 ℃.
The invention has the following beneficial effects: all raw materials in the synthetic route adopted by the invention are cheap and easily available; the operation is convenient, the post-treatment is simple, and the process safety is high; the reaction yield is high, the product purity is high, the production cost is greatly reduced, and the requirement of large-scale industrial production of the product can be fully met.
In order to make the aforementioned and other objects, features and advantages of the invention comprehensible, preferred embodiments accompanied with figures are described in detail below.
Drawings
In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings used in the description of the embodiments or the prior art will be briefly described below, it is obvious that the drawings in the following description are only some embodiments of the present invention, and for those skilled in the art, other drawings can be obtained according to the drawings without creative efforts.
FIG. 1 is a nuclear magnetic spectrum of example 1 of the present invention;
FIG. 2 is an HPLC chromatogram of example 1 of the present invention;
FIG. 3 is a nuclear magnetic spectrum of example 2 of the present invention;
FIG. 4 is an HPLC chromatogram of example 2 of the present invention;
FIG. 5 is a nuclear magnetic spectrum of example 3 of the present invention;
FIG. 6 is an HPLC chromatogram of example 3 of the present invention;
FIG. 7 is an HPLC chromatogram of example 3 of the present invention.
Detailed Description
The technical solutions in the embodiments of the present invention will be clearly and completely described below with reference to the drawings in the embodiments of the present invention, and it is obvious that the described embodiments are only a part of the embodiments of the present invention, and not all of the embodiments. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
In order to achieve the purpose, the invention provides a process method for preparing 5-methoxy-2-methylindole.
Example 1
380g of p-anisidine, 250g of hydroxyacetone, 1.5L of toluene and 1Kg of methanesulfonic acid are added in sequence into a 50L glass reaction flask with stirring at room temperature, and the mixture is stirred uniformly.
Further, heating the reaction solution to reflux reaction, and carrying out heat preservation and reflux reaction for 6 hours to finish the reaction.
Further, the reaction solution was distilled under reduced pressure to recover toluene and methanesulfonic acid, and the residue was recrystallized from t-butyl methyl ether, followed by vacuum oven drying to obtain 462g of a white-like solid powdery product with a yield of 92%.
HPLC purity of the product: 99.02 percent.
Nuclear magnetic data: 1H NMR (400MHz, d 6-DMSO): δ 10.68(s, 1H), 7.12(d, 1H), 6.89(d, 1H), 6.60(dd, 1H), 6.01(s, 1H), 3.71(s, 3H), 2.34(s, 3H).
Please refer to fig. 1 for nmr;
please refer to fig. 2 for HPLC spectra;
the structures are shown in Table 1.
Analytical results table
TABLE 1
As can be seen from fig. 1, fig. 2 and table 1, the synthesis route adopted in the present invention has high reaction yield and high product purity.
Example 2
Under stirring at room temperature, 4.2Kg of p-anisidine, 2.9Kg of hydroxyacetone and 25Kg of acetic acid were sequentially added to a 50L glass reaction vessel and stirred uniformly. Heating the reaction solution to reflux reaction, and carrying out heat preservation and reflux reaction for 8 hours to finish the reaction.
The reaction solution is decompressed and distilled to recover acetic acid, and the residue is recrystallized by acetonitrile and then dried by a vacuum oven to obtain 5.2Kg of off-white solid powder product with the yield of 94 percent.
HPLC purity of the product: 99.40 percent.
Nuclear magnetic data: 1H NMR (400MHz, d 6-DMSO): δ 10.68(s, 1H), 7.12(d, 1H), 6.89(d, 1H), 6.60(dd, 1H), 6.01(s, 1H), 3.71(s, 3H), 2.34(s, 3H).
The nuclear magnetic spectrum is shown in FIG. 3.
The HPLC chromatogram is shown in FIG. 4.
The analytical results are shown in Table 2.
Analytical results table
TABLE 2
As can be seen from fig. 3, fig. 4 and table 2, the synthesis route adopted in the present invention has high reaction yield and high product purity.
Example 3
Under stirring at room temperature, 4.5Kg of p-anisidine, 3.5Kg of hydroxyacetone, 30L of toluene, 2.3Kg of phosphorus pentoxide, and 3.9Kg of phosphoric acid were sequentially added to a 50L glass reaction vessel and stirred uniformly. Heating the reaction solution to reflux reaction, and carrying out heat preservation and reflux reaction for 6 hours to finish the reaction.
The reaction mixture was cooled to room temperature, washed twice with 20L of purified water, once with 20L of a saturated solution of sodium hydrogencarbonate, once with 20L of purified water, and once with 10L of saturated brine. Then, the toluene is recovered by reduced pressure distillation, and the residue is recrystallized by acetonitrile and then dried in a vacuum oven to obtain 5.3Kg of off-white solid powder product with the yield of 90 percent.
HPLC purity of the product: 99.08 percent.
Nuclear magnetic data: 1H NMR (400MHz, d 6-DMSO): δ 10.68(s, 1H), 7.12(d, 1H), 6.89(d, 1H), 6.60(dd, 1H), 6.01(s, 1H), 3.71(s, 3H), 2.34(s, 3H).
The NMR spectrum is shown in FIG. 5.
The HPLC chromatogram is shown in FIG. 6, and the corresponding analysis results are shown in Table 3.
Peak# | Ret.Time | Area | | Area% | |
1 | 1.567 | 15719 | 565 | 0.075 | |
2 | 2.203 | 68111 | 1914 | 0.324 | |
3 | 2.971 | 20871154 | 1417212 | 99.359 | |
4 | 10.364 | 33463 | 522 | 0.159 | |
5 | 10.800 | 1541 | 129 | 0.007 | |
6 | 12.461 | 15877 | 447 | 0.076 | |
Total | 21005865 | 1420789 | 100.000 |
TABLE 3
As can be seen from fig. 5, fig. 6 and table 3, the synthesis route employed in the present invention has high reaction yield and high product purity.
The HPLC chromatogram is shown in FIG. 7, and the corresponding analysis results are shown in Table 4.
Peak# | Ret.Time | Area | | Area% | |
1 | 2.197 | 3815 | 304 | 0.011 | |
2 | 2.974 | 32984492 | 2231371 | 99.086 | |
3 | 3.863 | 127057 | 7921 | 0.382 | |
4 | 10.361 | 66856 | 904 | 0.201 | |
5 | 14.375 | 106390 | 405 | 0.320 | |
Total | 33288610 | 2240905 | 100.000 |
TABLE 4
As can be seen from fig. 5, fig. 7 and table 4, the synthesis route employed in the present invention has high reaction yield and high product purity.
The principle and the implementation mode of the invention are explained by applying specific embodiments in the invention, and the description of the embodiments is only used for helping to understand the method and the core idea of the invention; meanwhile, for a person skilled in the art, according to the idea of the present invention, there may be variations in the specific embodiments and the application scope, and in summary, the content of the present specification should not be construed as a limitation to the present invention.
Claims (6)
2. The process of claim 1, wherein the catalyst is one or more of acetic acid, trifluoroacetic acid, aluminum trichloride, zinc chloride, titanium tetrachloride, tin chloride, methanesulfonic acid, trifluoromethanesulfonic acid, phosphoric acid, sulfuric acid, p-toluenesulfonic acid, eaton's reagent, phosphorus pentoxide, and benzenesulfonic acid.
3. The process of claim 1, wherein the reaction of methoxyaniline with hydroxyacetone is carried out in a solvent selected from the group consisting of dichloromethane, 1, 2-dichloroethane, o-dichlorobenzene, nitrobenzene, chlorobenzene, methanesulfonic acid, acetic acid, trifluoromethanesulfonic acid, diethyl ether, tert-butyl methyl ether, tetrahydrofuran, 2-methyltetrahydrofuran, dioxane, ethylene glycol dimethyl ether, ethylene glycol diethyl ether, diethylene glycol dimethyl ether, DMF, DMSO, toluene, xylene, ethyl acetate, propyl acetate, acetonitrile, dioxane.
4. The process for preparing 5-methoxy-2-methylindole according to claim 1, wherein the hydroxyacetone is used in an amount of: 0.5 to 10 equivalents.
5. The process for preparing 5-methoxy-2-methylindole according to claim 1, wherein the catalyst is used in an amount of: 0.001 to 100 equivalents.
6. The process for preparing 5-methoxy-2-methylindole according to claim 1, wherein the reaction temperature is-20 to 200 ℃.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010241252.9A CN111253297A (en) | 2020-03-31 | 2020-03-31 | Process method for preparing 5-methoxy-2-methylindole |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010241252.9A CN111253297A (en) | 2020-03-31 | 2020-03-31 | Process method for preparing 5-methoxy-2-methylindole |
Publications (1)
Publication Number | Publication Date |
---|---|
CN111253297A true CN111253297A (en) | 2020-06-09 |
Family
ID=70944474
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010241252.9A Pending CN111253297A (en) | 2020-03-31 | 2020-03-31 | Process method for preparing 5-methoxy-2-methylindole |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111253297A (en) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109748840A (en) * | 2017-11-02 | 2019-05-14 | 中国医学科学院药物研究所 | A kind of synthetic method of 2- substituted indole derivative |
-
2020
- 2020-03-31 CN CN202010241252.9A patent/CN111253297A/en active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109748840A (en) * | 2017-11-02 | 2019-05-14 | 中国医学科学院药物研究所 | A kind of synthetic method of 2- substituted indole derivative |
Non-Patent Citations (2)
Title |
---|
E. V. VOROB′EV,等: "Synthesis and rearrangements of 7H-pyrrolo[3,2-e][1,2,4]triazolo[1,5-c]-and 7H-pyrrolo[3,2-e][1,2,4]triazolo[4,3-c]pyrimidines", 《RUSSIAN CHEMICAL BULLETIN, INTERNATIONAL EDITION》 * |
H. J. ROTH,等: "Synthese von Indol- und Carbazol-Derivaten aus α-Hydroxyketonen und aromatischen Aminen", 《ARCHIV DER PHARMAZIE UND BERICHTE DER DEUTSCHEN PHARMAZEUTISCHEN GESELLSCHAFT》 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN108033922B (en) | Preparation method of 3-acyl quinoxalinone derivative | |
CN111253297A (en) | Process method for preparing 5-methoxy-2-methylindole | |
CN109627193B (en) | Diaryl azo oxygen compound with anti-tumor effect and synthesis method thereof | |
CN111362943A (en) | Preparation method of entecavir intermediate N4 | |
CN108299291B (en) | It is acylated the synthetic method of quinoline or isoquinilone derivatives | |
CN113045549B (en) | Pyrrole ethylene derivative and preparation method thereof | |
CN115215782A (en) | Preparation method of 4-bromoindole | |
Zhang et al. | Metal modified SSA as a heterogeneous catalyst to promote the cyclocondesation of o-aminobenzonitriles with cycloketones in water | |
CN106928142A (en) | 1,3 isoquinolin derovatives containing arylthio substitution and preparation method thereof | |
CN111635401A (en) | Copper complex promoted 7-fluoroimidazo [1,2-a ] pyridine synthesis method | |
CN111560022A (en) | Tetrahydrobenzofuran [3,2-d ] pyrimidine derivative and preparation method and application thereof | |
CN113816843A (en) | 2-hydroxy-9-fluorenone derivative and synthesis method and application thereof | |
CN111909098A (en) | hexahydro-5H-benzo [ d ] imidazole-5-ketone derivative and preparation method and application thereof | |
CN106397381A (en) | 2-alkoxy chromone oxime derivative and preparation method and application thereof | |
CN105001163A (en) | Tetra-substituted imidazole synthesis method | |
CN112479950B (en) | Preparation process of PIN1 inhibitor | |
CN113754715B (en) | Optical selective process synthesis method of (5R) -5-hydroxyl triptolide | |
CN115433124B (en) | Preparation method of 4-chloro-6-methoxy-7-benzyloxy quinoline | |
CN113651758B (en) | Synthetic method of benzo-hydrogenated imidazolone framework | |
CN113429333B (en) | Synthesis method of gatifloxacin intermediate | |
CN114349683B (en) | Amino protection and deprotection method for carbazole and carbazole-like derivatives | |
CN113582933A (en) | Preparation method of medical intermediate 4-chloro-5-cyanopyrimidine | |
CN113354573B (en) | Method for large-scale production of alpha, alpha-terpyridine | |
CN108191633A (en) | A kind of method for synthesizing homoanisic acid | |
CN110642818B (en) | Method for preparing benzofuran-2-carboxamide compound |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200609 |
|
RJ01 | Rejection of invention patent application after publication |